After a three-decade drought of new antibiotics to treat gonorrhea, the FDA has signed off on two first-in-class oral ...
Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...
Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...
As regulatory uncertainty around COVID vaccines continues to swirl, a new report from the Centers for Disease Control and Prevention (CDC) showcases the benefits of the immunizations among children | ...
As it shifts strategic direction to prioritize its recently acquired ENvue feeding tube placement system, NanoVibronix is changing its name to reflect the new focus. | As it shifts strategic direction ...
After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...
Abbott has put the ball back in Serena Williams’ court to serve up a high-profile endorsement of the Lingo over-the-counter ...
After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the ...
European legislators have reached a deal on a major rewrite of the region's pharma policies, pushing forward a framework ...